The Study of Immune Cell (T Cell) Activity in Patients With Paraneoplastic Neurologic Syndromes
The investigators believe that T cells, cells that are a part of the immune system, are what are causing the neurological problems while also attacking tumor cells. This protocol studies the clinical status of patients with paraneoplastic neurological disorder (PND) as well as their blood to understand the relationship between their neurological disease, their cancer, and their immune system.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Killer T Cell Activity in the Paraneoplastic Neurologic Syndromes|
|Study Start Date:||January 1995|
|Estimated Study Completion Date:||December 2015|
|Estimated Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
Patients with paraneoplastic neurological disorders (PNDs) provide a unique model for studying tumor immunity and neuronal autoimmunity. We hypothesize that T lymphocyte autoimmune dysfunction is involved in the pathogenesis of the paraneoplastic neurological syndromes, and that killer T cells are involved in the targeting and successful killing of tumor cells in these cancer patients. Furthermore, we postulate that this activity may provide a model for autoimmune brain disease. We will assess the immune responses in PND patients, correlate these with the clinical data (time course of disease, symptoms and signs, disability), and collect and archive clinical data, serum and cells from PND patients for current and future studies into the basic immune system phenomenon present in PND patients.
|Contact: Mayu Frank, NPfirstname.lastname@example.org|
|United States, New York|
|Rockefeller University Hospital||Recruiting|
|New York, New York, United States, 10021|
|Contact: Mayu Frank, NP 212-327-7443 email@example.com|
|Principal Investigator: Robert Darnell, MD, PHD|
|Principal Investigator:||Robert Darnell, MD, PHD||Rockefeller University|